Back to results
US 2012/0252039 A1Published application
Plasma kallikrein fragments as diagnostic biomarkers for lung cancers
AssigneeProtan Bio Co., Ltd.
InventorsJe-Yeol CHO, Jae-Yong PARK, Seung-Jin LEE
Life of this patent
Estimating the term…
Abstract
Disclosed herein are diagnostic markers for lung cancer, isolated from serum glycoproteins. The disclosed diagnostic markers for lung cancer are specifically expressed only in the sera of lung cancer patients at high levels, and thus will be very useful for diagnosing lung cancer and estimating disease progression and treatment.
Claims7
A method for diagnosing lung cancer in a subject, which comprises the steps of:
- (a) bringing a biological sample into contact with an antibody binding specifically to the diagnostic marker of plasma kallikrein (KLKB1) fragment;
- and
- (b) detecting the formation of an antigen-antibody complex.
A method for diagnosing lung cancer, which comprises the steps of:
- (a) removing a plasma kallikrein fragment and the heavy chain precursor form thereof from the serum of a subject;
- (b) bringing the serum, from which the plasma kallikrein fragment and the heavy chain precursor form thereof had been removed in the step (a), into contact with an antibody specific for a region comprising the H4 domain of the plasma kallikrein fragment;
- and
- (c) detecting the formation of an antigen-antibody complex.
1 more element
Dependencies are inferred from the claim text.